Comparative Pharmacology
Head-to-head clinical analysis: TRIAMCINOLONE versus ZYLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAMCINOLONE versus ZYLET.
TRIAMCINOLONE vs ZYLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and anti-allergic effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2 activity, reducing prostaglandin and leukotriene synthesis. Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Intramuscular: 40-80 mg as a single dose; Intra-articular: 5-40 mg depending on joint size; Topical: Apply thin layer 2-4 times daily; Oral: 4-48 mg/day in divided doses.
One to two drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours. In severe cases, every 1 to 2 hours for the first 24 to 48 hours.
None Documented
None Documented
Clinical Note
moderateTriamcinolone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Triamcinolone is combined with Gatifloxacin."
Clinical Note
moderateTriamcinolone + Rosoxacin
"The risk or severity of adverse effects can be increased when Triamcinolone is combined with Rosoxacin."
Clinical Note
moderateTriamcinolone + Levofloxacin
"The risk or severity of adverse effects can be increased when Triamcinolone is combined with Levofloxacin."
Clinical Note
moderateThe terminal elimination half-life of triamcinolone is approximately 2-5 hours (mean 3 hours) following intravenous administration. Clinically, this short half-life supports multiple daily dosing for systemic effects, but duration of action is longer due to receptor occupancy.
ZYLET: not applicable (fixed-dose combination); Loteprednol: 2-3 hours; Tobramycin: 2-3 hours. Clinical context: no accumulation with qid dosing.
Triamcinolone is primarily metabolized hepatically; unchanged drug and metabolites are excreted renally. Approximately 25-30% of a dose is excreted in urine as unchanged triamcinolone, with the remainder as metabolites. Fecal excretion accounts for less than 10%.
Renal (30% unchanged), biliary/fecal (70% as metabolites)
Category D/X
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination (Ophthalmic)
Triamcinolone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Triamcinolone is combined with Trovafloxacin."